La photothérapie dynamique de la dégénérescence maculaire liée è l'âge avec ou sans thérapie aux antioxydants

ment emergent and serious non-ocular events *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; HR: Hazard ratio GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. 1 Downgraded for imprecision 4 Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration (Review)

show abstract

La photothérapie dynamique de la dégénérescence maculaire liée è l'âge avec ou sans thérapie aux antioxydants

Cited by 8 publications

References 7 publications

Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration

Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration

Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration

Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration

Contact Info

Product

Resources

About